{"url":"https://lda.senate.gov/api/v1/filings/ef6750a5-e416-4bdd-80a8-c3a7d1382b08/","filing_uuid":"ef6750a5-e416-4bdd-80a8-c3a7d1382b08","filing_type":"RA","filing_type_display":"Registration - Amendment","filing_year":2015,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/ef6750a5-e416-4bdd-80a8-c3a7d1382b08/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jonah C. Houts","dt_posted":"2015-07-18T11:18:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"300 New Jersey Avenue, NW, #600","registrant_address_2":null,"registrant_different_address":null,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":294416,"url":"https://lda.senate.gov/api/v1/registrants/294416/","house_registrant_id":37412,"name":"EXPRESS SCRIPTS, INC.","description":"pharmacy benefit management","address_1":"300 New Jersey Avenue, NW, #600","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KRISTIN JULASON DAMATO","contact_telephone":"+1 202-719-5557","dt_updated":"2022-04-06T16:08:29.502706-04:00"},"client":{"id":178833,"url":"https://lda.senate.gov/api/v1/clients/178833/","client_id":12,"name":"EXPRESS SCRIPTS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-06-15"},"lobbying_activities":[{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"POS","general_issue_code_display":"Postal","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA);  HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA);  S1431(Rx Abuse Prevention & Treatment).","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":62397,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"DONNELLY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}